Kiniksa Pharmaceuticals International (KNSA) Insider Trading & Ownership $33.40 -0.10 (-0.30%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage53.48%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)8Amount OfInsider Selling(Last 12 Months)$30.49M Get KNSA Insider Trade Alerts Want to know when executives and insiders are buying or selling Kiniksa Pharmaceuticals International stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KNSA Insider Buying and Selling by Quarter Kiniksa Pharmaceuticals International Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/18/2025Eben TessariCOOSell16,200$33.77$547,074.00 8/14/2025Thomas MalleyDirectorSell78,233$33.09$2,588,729.97 8/13/2025Thomas MalleyDirectorSell50,129$33.32$1,670,298.28 8/12/2025Thomas MalleyDirectorSell49,407$32.40$1,600,786.80 8/6/2025John F PaoliniInsiderSell29,325$32.55$954,528.75 8/5/2025Eben TessariCOOSell138,614$33.20$4,601,984.80 8/4/2025Mark RagosaCFOSell18,889$32.89$621,259.21 8/4/2025Michael R MegnaCAOSell17,000$32.35$549,950.00 7/14/2025Eben TessariCOOSell18,900$28.72$542,808.00 6/16/2025Eben TessariCOOSell17,300$28.28$489,244.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/11/2025Barry D QuartDirectorSell12,336$30.39$374,891.04 6/11/2025Eben TessariCOOSell45,042$30.51$1,374,231.42 6/10/2025Barry D QuartDirectorSell8,212$30.36$249,316.32 6/10/2025Eben TessariCOOSell15,506$30.46$472,312.76 6/9/2025Barry D QuartDirectorSell6,900$30.26$208,794.00 6/9/2025Eben TessariCOOSell10,319$30.38$313,491.22 6/3/2025Mark RagosaCFOSell18,299$28.80$527,011.20 6/3/2025Michael R MegnaCAOSell15,211$28.75$437,316.25 6/3/2025Ross MoatInsiderSell27,594$29.02$800,777.88 5/28/2025Sanj K PatelCEOSell62,116$27.33$1,697,630.28 5/27/2025Sanj K PatelCEOSell19,317$27.01$521,752.17 5/23/2025Sanj K PatelCEOSell4,837$27.00$130,599.00 5/19/2025Eben TessariCOOSell12,000$26.41$316,920.00 5/13/2025Sanj K PatelCEOSell2,872$27.03$77,630.16 5/8/2025Sanj K PatelCEOSell101$27.00$2,727.00 5/7/2025John F PaoliniInsiderSell200$27.00$5,400.00 5/7/2025Michael R MegnaCAOSell17,647$26.69$470,998.43 5/5/2025Ross MoatInsiderSell6,272$28.00$175,616.00 5/1/2025Ross MoatInsiderSell23,234$28.02$651,016.68 4/30/2025Mark RagosaCFOSell21,254$26.95$572,795.30 4/29/2025Ross MoatInsiderSell64,035$25.21$1,614,322.35 4/21/2025Ross MoatInsiderSell18,259$20.29$370,475.11 4/14/2025Eben TessariCOOSell12,000$20.48$245,760.00 3/19/2025Mark RagosaCFOSell8,879$23.10$205,104.90 3/17/2025Mark RagosaCFOSell11,464$23.10$264,818.40 3/12/2025Mark RagosaCFOSell36,372$22.25$809,277.00 3/12/2025Michael R MegnaCAOSell9,051$22.45$203,194.95 2/10/2025Eben TessariCOOSell14,000$19.57$273,980.00 1/13/2025Eben TessariCOOSell14,000$18.24$255,360.00 12/5/2024Mark RagosaCFOSell1,123$21.25$23,863.75 Trump’s national nightmare is here (Ad)Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.Watch the National Emergency broadcast here12/3/2024Mark RagosaCFOSell8,969$21.45$192,385.05 10/15/2024Eben TessariCOOSell17,000$26.87$456,790.00 9/23/2024Eben TessariCOOSell17,500$24.99$437,325.00 9/3/2024John F PaoliniInsiderSell60,692$26.12$1,585,275.04 (Data available from 1/1/2013 forward) KNSA Insider Trading Activity - Frequently Asked Questions Who is on Kiniksa Pharmaceuticals International's Insider Roster? The list of insiders at Kiniksa Pharmaceuticals International includes Barry D Quart, Eben Tessari, John F Paolini, Mark Ragosa, Michael R Megna, Ross Moat, Sanj K Patel, and Thomas Malley. Learn more on insiders at KNSA. What percentage of Kiniksa Pharmaceuticals International stock is owned by insiders? 53.48% of Kiniksa Pharmaceuticals International stock is owned by insiders. Learn more on KNSA's insider holdings. Which Kiniksa Pharmaceuticals International insiders have been selling company stock? The following insiders have sold KNSA shares in the last 24 months: Barry D Quart ($833,001.36), Eben Tessari ($10,798,206.20), John F Paolini ($3,636,045.79), Mark Ragosa ($4,057,622.73), Michael R Megna ($2,478,119.70), Ross Moat ($3,612,208.02), Sanj K Patel ($6,312,966.79), and Thomas Malley ($5,859,815.05). How much insider selling is happening at Kiniksa Pharmaceuticals International? Insiders have sold a total of 1,356,577 Kiniksa Pharmaceuticals International shares in the last 24 months for a total of $37,587,985.64 sold. Kiniksa Pharmaceuticals International Key ExecutivesMr. Sanj K. Patel (Age 55)CEO & Chairman of the Board Compensation: $1.57M5 recent tradesMr. Eben Tessari (Age 42)Senior VP & COO Compensation: $733.29k9 recent tradesDr. John F. Paolini FACC (Age 59)M.D., Ph.D., Senior VP & Chief Medical Officer Compensation: $855.79kMr. Mark Ragosa C.F.A. (Age 50)Senior VP & CFO Mr. Michael R. Megna CPA (Age 53)Chief Accounting Officer & Group VP of Finance 4 recent tradesMr. Chad MorinSenior VP & Chief Compliance OfficerMs. Madelyn Demsky Zeylikman (Age 50)SVP, General Counsel & Secretary More Insider Trading Tools from MarketBeat Related Companies BBIO Insider Transactions VRNA Insider Transactions ELAN Insider Transactions BPMC Insider Transactions ROIV Insider Transactions GRFS Insider Transactions RVMD Insider Transactions RYTM Insider Transactions RNA Insider Transactions NUVL Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:KNSA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access